Direct and crossover effects of brinzolamide, betaxolol, and latanoprost on choroidal thickness

OKUTUCU M., FINDIK H., ASLAN M. G.

CUTANEOUS AND OCULAR TOXICOLOGY, vol.38, no.2, pp.196-200, 2019 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.1080/15569527.2019.1575390
  • Journal Name: CUTANEOUS AND OCULAR TOXICOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.196-200
  • Keywords: Brinzolamide, betaxolol, latanoprost, choroid, thickness, OCULAR BLOOD-FLOW, INTRAOCULAR-PRESSURE, TIMOLOL, PHARMACOKINETICS, PATHOGENESIS, DORZOLAMIDE, PROGRESSION, 0.5-PERCENT, RISK
  • Recep Tayyip Erdoğan University Affiliated: Yes

Abstract

Purpose: To investigate the acute effects of brinzolamide, betaxolol, and latanoprost (drugs commonly used in the medical management of glaucoma) on choroidal thickness using enhanced depth imaging optical coherence tomography (EDI-OCT). Methods: Ninety healthy volunteers were evaluated in this prospective study. Participants were randomly divided into 3 groups. Brinzolamide, betaxolol, and latanoprost were administered into the left eyes of the first group (n = 30), second group (n = 30), and third group (n = 30), respectively, and artificial tear (Sodium hyaluronate) was instilled into the right eyes of all participants. Subfoveal choroidal thickness (SFCT) was measured using EDI-OCT before and 45 minutes after administration of the antiglaucomatous drops. Results: SFCT revealed a significant increase in the left eye (administered antiglaucomatous drop) in the brinzolamide (p = 0.001) and betaxolol groups (p = 0.049) and a significant increase also in the right eye (administered artificial drop) in the brinzolamide (p = 0.001) and betaxolol groups (p = 0.001). However, SFCT did not reveal a significant increase in the left eye (p = 0.213) or in the right eye (p = 0.062) in the latanoprost group. Conclusion: Brinzolamide and betaxolol caused an increase in SFCT, while latanoprost had no significant effect on SFCT.